Integration of molecular pathology in clinical research

Dr. Fred Hirsch

MD, PhD, Full Prof.
Professor of Medicine and Pathology
Division of Medical Oncology
University of Colorado, USA
CEO IASLC

Second-line adenocarcinoma:
Combination therapy is a new opportunity beyond immunoteraphy

Dr. Christian Rolfo

MD, PhD, MBAh
Head of Phase I - Early Clinical Trials Unit
Director of Clinical Trials Management Program
Antwerp University Hospital &
Center for Oncological Research (CORE),
Antwerp University, Belgium

Immunotherapy in NSCLC

Dr. Christian Caglevic

Medical Oncologist
Instituto Oncológico Fundación
Arturo López Pérez. Santiago, Chile